Table. 2.

Homogeneity assessment for three levels of AMH EQA materials

Vial no. Level I Level II Level III



Mean±SD (ng/mL) CV (%) Mean±SD (ng/mL) CV (%) Mean±SD (ng/mL) CV (%)
Vial 1 (n=3) 0.49±0.02 3.53 5.77±0.03 0.50 9.76±0.19 1.99
Vial 2 (n=3) 0.49±0.01 1.19 5.91±0.13 2.20 9.48±0.03 0.28
Vial 3 (n=3) 0.51±0.01 2.28 5.61±0.13 2.23 9.61±0.25 2.57
Vial 4 (n=3) 0.48±0.01 2.42 5.65±0.18 3.15 9.32±0.28 2.98
Vial 5 (n=3) 0.49±0.01 1.17 6.02±0.08 1.38 9.78±0.33 3.34
Overall (n=15) 0.49±0.01 2.12 5.93±0.11 1.89 9.78±0.33 2.23
Total CV (%) 2.91 2.40 2.80
P-value* 0.0839 0.1582 0.1832
Sbb 0.009 ng/mL (1.78%) 0.073 ng/mL (1.26%) 0.132 ng/mL (1.38%)
Sr 0.011 ng/mL (2.29%) 0.122 ng/mL (2.09%) 0.238 ng/mL (2.48%)

Abbreviations: AMH, anti-Müllerian hormone; EQA, external quality assurance; SD, standard deviation; CV, coefficient of variation; Sbb, between-vial standard deviation; Sr, repeatability standard deviation.

*Significant results with P-values less than 0.05 (by analysis of variance).

J Lab Med Qual Assur 2020;42:211~217 https://doi.org/10.15263/jlmqa.2020.42.4.211
© Lab Med Qual Assur